

HELIOS CENTRE
Libuse Gilka, M.D.
Ottawa, Ontario K2G 6B1

Tel. (613) 723-7241, 723-7287, Fax (613) 224-3425, e-mail: heliosctr@sympatico.ca

Mr. Gaston Naessens
CERBE Distribution Inc.
5270 Mills Street
Rock Forest, Quebec J1N 3B6

February 27, 2004

Dear Mr. Naessens,

This letter is pursuant to the faxed communication dated January 19, 2004 which I received from Health Canada, Therapeutic Products Directorate re: Release of 714X through the Special Access Programme (SAP). As mentioned in the letter from Health Canada, I have requested access to 714X on numerous occasions in the past and, therefore, have incorporated, to a certain extent, its use into my practice.

In spite of the inconvenience that 714X has to be administered as a daily injection, the patients using 714X under my medical care were always willing to use 714X because they felt that it improves the quality of their lives.

Generally, I have observed that 714X helps to shrink the tumors, reduces or even eliminates pain and helps to promote weight gain or weight stabilization. The only side effect is a burning sensation in some patients around the site of injection.

To summarize my observations of the patients who received 714X:


1. None of my patients who were using 714X had any adverse reactions or side effects apart from occasional burning sensations at or around the site of injection.
2. Practically all patients using 714X claimed that their pain lessened or disappeared and that the quality of their lives improved markedly.

I can therefore testify that, for those patients suffering serious or debilitating illnesses for which I have requested 714X within the special Access Programme, I have observed that 714X benefited them without causing any undesirable adverse reactions or side effects and that this has justified my professional judgement to use this product.

The experience I acquired with this product resulted in my recommending it to others for whom this product was well indicated because conventional treatments had been exhausted or proven ineffective.

I may be willing to work with a manufacturer that is interested in sponsoring the development of a clinical trial as I would like my patients to keep on having access to your product.

Best regards,



Libuse Gilka, M.D.

HELIOS CENTRE

Libuse Gilka, M.D.

88 CentrepoinTE Dr., Nepean ON K2G 6B1
Tel: (613) 723-7241, 723-7287 Fax: (613) 224-3425

By appointment only